Back to Search
Start Over
The Landmark Series: Neoadjuvant Endocrine Therapy for Breast Cancer
- Source :
- Annals of Surgical Oncology. 27:3393-3401
- Publication Year :
- 2020
- Publisher :
- Springer Science and Business Media LLC, 2020.
-
Abstract
- Patients with estrogen receptor (ER)-positive breast cancer generally do not have significant response to neoadjuvant chemotherapy. In these patients, neoadjuvant endocrine therapy (NET) is an alternative for those who may benefit from tumor downsizing prior to surgery. This article reviews clinical trials that have defined the role of NET. Cumulatively, these trials demonstrate that NET is effective in downsizing ER-positive breast tumors. Aromatase inhibitors are preferred in postmenopausal patients. An aromatase inhibitor with ovarian suppression is effective in premenopausal patients. While trials to date have shown the effectiveness of NET to facilitate breast conservation, they have provided little data regarding optimal axillary management.
- Subjects :
- Oncology
medicine.medical_specialty
Antineoplastic Agents, Hormonal
medicine.drug_class
medicine.medical_treatment
Estrogen receptor
Breast Neoplasms
03 medical and health sciences
0302 clinical medicine
Breast cancer
Surgical oncology
Internal medicine
Humans
Medicine
Aromatase
Neoadjuvant therapy
Clinical Trials as Topic
Aromatase inhibitor
biology
Aromatase Inhibitors
business.industry
Patient Selection
medicine.disease
Neoadjuvant Therapy
Postmenopause
Clinical trial
Tamoxifen
Premenopause
Receptors, Estrogen
Estrogen
Lymphatic Metastasis
030220 oncology & carcinogenesis
Axilla
biology.protein
Lymph Node Excision
Female
030211 gastroenterology & hepatology
Surgery
Lymph Nodes
business
Subjects
Details
- ISSN :
- 15344681 and 10689265
- Volume :
- 27
- Database :
- OpenAIRE
- Journal :
- Annals of Surgical Oncology
- Accession number :
- edsair.doi.dedup.....a0392b7d09aa04f15381905170c64854